transforming drug development at lilly
TRANSCRIPT
![Page 1: Transforming Drug Development at Lilly](https://reader030.vdocument.in/reader030/viewer/2022032504/55c389d8bb61eb38478b45cb/html5/thumbnails/1.jpg)
Transforming Drug Development It’s not just for researchers – you can participate!
Health 2.0 New Orleans November 21, 2013 Thomas Krohn, RPh, MBA Eli Lilly and Company
![Page 2: Transforming Drug Development at Lilly](https://reader030.vdocument.in/reader030/viewer/2022032504/55c389d8bb61eb38478b45cb/html5/thumbnails/2.jpg)
Drug Development - today
Precompetitive Competitive patent
Innovation Process
![Page 3: Transforming Drug Development at Lilly](https://reader030.vdocument.in/reader030/viewer/2022032504/55c389d8bb61eb38478b45cb/html5/thumbnails/3.jpg)
Business Model Performance
Source: FDA.gov
Productivity Down, Costs Up Future revenues under pressure
Unsustainable Business Model
![Page 4: Transforming Drug Development at Lilly](https://reader030.vdocument.in/reader030/viewer/2022032504/55c389d8bb61eb38478b45cb/html5/thumbnails/4.jpg)
Moore’s vs. Eroom’s Law
![Page 5: Transforming Drug Development at Lilly](https://reader030.vdocument.in/reader030/viewer/2022032504/55c389d8bb61eb38478b45cb/html5/thumbnails/5.jpg)
The Far Side by Gary Larson
![Page 6: Transforming Drug Development at Lilly](https://reader030.vdocument.in/reader030/viewer/2022032504/55c389d8bb61eb38478b45cb/html5/thumbnails/6.jpg)
Incremental Improvement
![Page 7: Transforming Drug Development at Lilly](https://reader030.vdocument.in/reader030/viewer/2022032504/55c389d8bb61eb38478b45cb/html5/thumbnails/7.jpg)
![Page 8: Transforming Drug Development at Lilly](https://reader030.vdocument.in/reader030/viewer/2022032504/55c389d8bb61eb38478b45cb/html5/thumbnails/8.jpg)
Disruptive Innovation
to S1'
to S2
S1
Time
Per
form
ance
Disruptive Change
Simpler, Faster, Cheaper?
![Page 9: Transforming Drug Development at Lilly](https://reader030.vdocument.in/reader030/viewer/2022032504/55c389d8bb61eb38478b45cb/html5/thumbnails/9.jpg)
Disruption in motion
![Page 10: Transforming Drug Development at Lilly](https://reader030.vdocument.in/reader030/viewer/2022032504/55c389d8bb61eb38478b45cb/html5/thumbnails/10.jpg)
Generation and Access to Data
![Page 11: Transforming Drug Development at Lilly](https://reader030.vdocument.in/reader030/viewer/2022032504/55c389d8bb61eb38478b45cb/html5/thumbnails/11.jpg)
Patient Digital Monitoring
![Page 12: Transforming Drug Development at Lilly](https://reader030.vdocument.in/reader030/viewer/2022032504/55c389d8bb61eb38478b45cb/html5/thumbnails/12.jpg)
Patient Communities
Patients as microexperts – not subjects
![Page 13: Transforming Drug Development at Lilly](https://reader030.vdocument.in/reader030/viewer/2022032504/55c389d8bb61eb38478b45cb/html5/thumbnails/13.jpg)
Patient-Driven Research
![Page 14: Transforming Drug Development at Lilly](https://reader030.vdocument.in/reader030/viewer/2022032504/55c389d8bb61eb38478b45cb/html5/thumbnails/14.jpg)
The Disruption
Power to the Patient
![Page 15: Transforming Drug Development at Lilly](https://reader030.vdocument.in/reader030/viewer/2022032504/55c389d8bb61eb38478b45cb/html5/thumbnails/15.jpg)
Clinical Research as part of Healthcare
Public Perception • 94% of people recognize the importance of participating in clinical research
in order to assist in the advancement of medical science. Yet 75% of the general public state they have little to no knowledge about the clinical research enterprise and the participation process. (www.centerwatch.com)
• Less than five percent of cancer patients participate in clinical trials. If ten percent participated, studies could be completed in one year, instead of the three-five years that studies currently require. (National Cancer Institute)
• It's not uncommon for your cancer doctor or treatment team to discuss the option of a clinical trial as the best treatment choice for your cancer type. (www.mayoclinic.com)
Standard of Care Clinical Trial Info & Innovation
![Page 16: Transforming Drug Development at Lilly](https://reader030.vdocument.in/reader030/viewer/2022032504/55c389d8bb61eb38478b45cb/html5/thumbnails/16.jpg)
ClinicalTrials.Gov and Patients
98,000,000 Pageviews/Month1
Sources: 1) clinicaltrials.gov site 2) D. Zarin 2007 Overview
47,000,000 Patient driven pageviews/Month
2
What if….?
![Page 17: Transforming Drug Development at Lilly](https://reader030.vdocument.in/reader030/viewer/2022032504/55c389d8bb61eb38478b45cb/html5/thumbnails/17.jpg)
1
Patient-Centric Design
Patient Voice
2
Patient-Centric Study Representation & Voice
Study Representation
Informed Consent Document Ct.Gov
Study Design
Open
Platform
Patients
• Clear eligibility • Risk/Benefit • My doctor’s role • Study treatment • Time to results • Logistics
Design Challenge
ctdesign.challengepost.com
November 14
![Page 18: Transforming Drug Development at Lilly](https://reader030.vdocument.in/reader030/viewer/2022032504/55c389d8bb61eb38478b45cb/html5/thumbnails/18.jpg)
Patient-Centric Information
Open
Platform
Patients
labs.lillycoi.com
![Page 19: Transforming Drug Development at Lilly](https://reader030.vdocument.in/reader030/viewer/2022032504/55c389d8bb61eb38478b45cb/html5/thumbnails/19.jpg)
Clinical Open Innovation
Open
Platform
Patients
api.lillycoi.com
Daily Updates
Open Web
REST API
![Page 20: Transforming Drug Development at Lilly](https://reader030.vdocument.in/reader030/viewer/2022032504/55c389d8bb61eb38478b45cb/html5/thumbnails/20.jpg)
Enabling patient matching to studies
Open
Platform
Patients
api.lillycoi.com
Daily Updates
Open Web
REST API
Patient Study “Target Profiles”
Study Sponsors
Patient & Communities
Personal Electronic Medical Records
Match Process
Consent to
Match
![Page 21: Transforming Drug Development at Lilly](https://reader030.vdocument.in/reader030/viewer/2022032504/55c389d8bb61eb38478b45cb/html5/thumbnails/21.jpg)
Patient Engagement App Challenge
http://patientengagement.challengepost.com
![Page 22: Transforming Drug Development at Lilly](https://reader030.vdocument.in/reader030/viewer/2022032504/55c389d8bb61eb38478b45cb/html5/thumbnails/22.jpg)
Join the transformation
• Learn the business model • Understand patient needs • Identify options for value creation • Explore open data and patient engagement • Participate in challenges
Most people are afraid of making mistakes. Leaders are afraid of missing opportunities.
![Page 23: Transforming Drug Development at Lilly](https://reader030.vdocument.in/reader030/viewer/2022032504/55c389d8bb61eb38478b45cb/html5/thumbnails/23.jpg)
References
• Website: www.lillycoi.com • API: api.lillycoi.com • App Lab: labs.lillycoi.com • Whitepaper: link • Twitter: @Lilly_COI, @takmad
![Page 24: Transforming Drug Development at Lilly](https://reader030.vdocument.in/reader030/viewer/2022032504/55c389d8bb61eb38478b45cb/html5/thumbnails/24.jpg)
Thanks!